Literature DB >> 18417476

Osteopontin negatively regulates parathyroid hormone receptor signaling in osteoblasts.

Noriaki Ono1, Kazuhisa Nakashima, Susan R Rittling, Ernestina Schipani, Tadayoshi Hayata, Kunimichi Soma, David T Denhardt, Henry M Kronenberg, Yoichi Ezura, Masaki Noda.   

Abstract

Systemic hormonal control exerts its effect through the regulation of local target tissues, which in turn regulate upstream signals in a feedback loop. The parathyroid hormone (PTH) axis is a well defined hormonal signaling system that regulates calcium levels and bone metabolism. To understand the interplay between systemic and local signaling in bone, we examined the effects of deficiency of the bone matrix protein osteopontin (OPN) on the systemic effects of PTH specifically within osteoblastic cell lineages. Parathyroid hormone receptor (PPR) transgenic mice expressing a constitutively active form of the receptor (caPPR) specifically in cells of the osteoblast lineage have a high bone mass phenotype. In these mice, OPN deficiency further increased bone mass. This increase was associated with conversion of the major intertrabecular cell population from hematopoietic cells to stromal/osteoblastic cells and parallel elevations in histomorphometric and biochemical parameters of bone formation and resorption. Treatment with small interfering RNA (siRNA) for osteopontin enhanced H223R mutant caPPR-induced cAMP-response element (CRE) activity levels by about 10-fold. Thus, in addition to the well known calcemic feedback system for PTH, local feedback regulation by the bone matrix protein OPN also plays a significant role in the regulation of PTH actions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18417476      PMCID: PMC3762377          DOI: 10.1074/jbc.M800005200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

Review 1.  Hyperparathyroid and hypoparathyroid disorders.

Authors:  S J Marx
Journal:  N Engl J Med       Date:  2000-12-21       Impact factor: 91.245

Review 2.  Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival.

Authors:  D T Denhardt; M Noda; A W O'Regan; D Pavlin; J S Berman
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

3.  Therapeutic targeting of a stem cell niche.

Authors:  Gregor B Adams; Roderick P Martin; Ian R Alley; Karissa T Chabner; Kenneth S Cohen; Laura M Calvi; Henry M Kronenberg; David T Scadden
Journal:  Nat Biotechnol       Date:  2007-01-21       Impact factor: 54.908

4.  Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration.

Authors:  R Zohar; N Suzuki; K Suzuki; P Arora; M Glogauer; C A McCulloch; J Sodek
Journal:  J Cell Physiol       Date:  2000-07       Impact factor: 6.384

Review 5.  Clinical review 123: Anabolic therapy for osteoporosis.

Authors:  C J Rosen; J P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2001-03       Impact factor: 5.958

6.  Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone.

Authors:  L M Calvi; N A Sims; J L Hunzelman; M C Knight; A Giovannetti; J M Saxton; H M Kronenberg; R Baron; E Schipani
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

7.  The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway.

Authors:  Y H Lin; H F Yang-Yen
Journal:  J Biol Chem       Date:  2001-10-05       Impact factor: 5.157

Review 8.  Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk--a meta-analysis.

Authors:  P Vestergaard; N R Jorgensen; L Mosekilde; P Schwarz
Journal:  Osteoporos Int       Date:  2006-09-02       Impact factor: 4.507

9.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

Authors:  R M Neer; C D Arnaud; J R Zanchetta; R Prince; G A Gaich; J Y Reginster; A B Hodsman; E F Eriksen; S Ish-Shalom; H K Genant; O Wang; B H Mitlak
Journal:  N Engl J Med       Date:  2001-05-10       Impact factor: 91.245

10.  Enhancement of osteoclastic bone resorption and suppression of osteoblastic bone formation in response to reduced mechanical stress do not occur in the absence of osteopontin.

Authors:  M Ishijima; S R Rittling; T Yamashita; K Tsuji; H Kurosawa; A Nifuji; D T Denhardt; M Noda
Journal:  J Exp Med       Date:  2001-02-05       Impact factor: 14.307

View more
  13 in total

1.  Osteopontin deficiency enhances parathyroid hormone/ parathyroid hormone related peptide receptor (PPR) signaling-induced alteration in tooth formation and odontoblastic morphology.

Authors:  Maki Morishita; Noriaki Ono; Kentano Miyai; Tomomi Nakagawa; Ryo Hanyu; Masashi Nagao; Paksinee Kamolratanakul; Takuya Notomi; Susan R Rittling; David T Denhardt; Henry M Kronenberg; Yoichi Ezura; Tadayoshi Hayata; Tetsuya Nakamoto; Masaki Noda
Journal:  Tissue Cell       Date:  2011-04-21       Impact factor: 2.466

2.  Factors that affect postnatal bone growth retardation in the twitcher murine model of Krabbe disease.

Authors:  Miguel Agustin Contreras; William Louis Ries; Srinivasan Shanmugarajan; Gonzalo Arboleda; Inderjit Singh; Avtar Kaur Singh
Journal:  Biochim Biophys Acta       Date:  2010-05-02

3.  Osteoclastogenic activity and RANKL expression are inhibited in osteoblastic cells expressing constitutively active Gα(12) or constitutively active RhoA.

Authors:  Jun Wang; Paula H Stern
Journal:  J Cell Biochem       Date:  2010-12-15       Impact factor: 4.429

4.  Osteopontin regulates anabolic effect in human menopausal osteoporosis with intermittent parathyroid hormone treatment.

Authors:  T-I Chiang; I-C Chang; H-S Lee; H Lee; C-H Huang; Y-W Cheng
Journal:  Osteoporos Int       Date:  2010-08-24       Impact factor: 4.507

5.  Increased serum osteopontin is a risk factor for osteoporosis in menopausal women.

Authors:  I-C Chang; T-I Chiang; K-T Yeh; H Lee; Y-W Cheng
Journal:  Osteoporos Int       Date:  2010-03-18       Impact factor: 4.507

6.  Protein-disulfide isomerase-associated 3 (Pdia3) mediates the membrane response to 1,25-dihydroxyvitamin D3 in osteoblasts.

Authors:  Jiaxuan Chen; Rene Olivares-Navarrete; Yun Wang; Tyler R Herman; Barbara D Boyan; Zvi Schwartz
Journal:  J Biol Chem       Date:  2010-09-15       Impact factor: 5.157

7.  Salt-inducible kinases dictate parathyroid hormone 1 receptor action in bone development and remodeling.

Authors:  Shigeki Nishimori; Maureen J O'Meara; Christian D Castro; Hiroshi Noda; Murat Cetinbas; Janaina da Silva Martins; Ugur Ayturk; Daniel J Brooks; Michael Bruce; Mizuki Nagata; Wanida Ono; Christopher J Janton; Mary L Bouxsein; Marc Foretz; Rebecca Berdeaux; Ruslan I Sadreyev; Thomas J Gardella; Harald Jüppner; Henry M Kronenberg; Marc N Wein
Journal:  J Clin Invest       Date:  2019-12-02       Impact factor: 14.808

Review 8.  The effect of five proteins on stem cells used for osteoblast differentiation and proliferation: a current review of the literature.

Authors:  P Chatakun; R Núñez-Toldrà; E J Díaz López; C Gil-Recio; E Martínez-Sarrà; F Hernández-Alfaro; E Ferrés-Padró; L Giner-Tarrida; M Atari
Journal:  Cell Mol Life Sci       Date:  2013-04-09       Impact factor: 9.261

9.  High-throughput screening of mouse gene knockouts identifies established and novel skeletal phenotypes.

Authors:  Robert Brommage; Jeff Liu; Gwenn M Hansen; Laura L Kirkpatrick; David G Potter; Arthur T Sands; Brian Zambrowicz; David R Powell; Peter Vogel
Journal:  Bone Res       Date:  2014-10-28       Impact factor: 13.567

10.  Osteopontin expression in reactive lesions of gingiva.

Authors:  Rathinam Elanagai; Veeran Veeravarmal; Ramdas Madhavan Nirmal
Journal:  J Appl Oral Sci       Date:  2015 Jan-Feb       Impact factor: 2.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.